Published in J Acquir Immune Defic Syndr on May 01, 1999
Candida albicans secreted aspartyl proteinases in virulence and pathogenesis. Microbiol Mol Biol Rev (2003) 4.07
Immunopathogenesis of oropharyngeal candidiasis in human immunodeficiency virus infection. Clin Microbiol Rev (2004) 1.48
Oropharyngeal candidiasis in the era of antiretroviral therapy. Oral Surg Oral Med Oral Pathol Oral Radiol Endod (2010) 1.22
Biotyping and virulence properties of skin isolates of Candida parapsilosis. J Clin Microbiol (1999) 1.10
Effects of long-term use of HAART on oral health status of HIV-infected subjects. J Oral Pathol Med (2010) 1.07
Oral manifestations in HIV infection: fungal and bacterial infections, Kaposi's sarcoma. Med Microbiol Immunol (2003) 0.93
Genetic variation of innate immune genes in HIV-infected african patients with or without oropharyngeal candidiasis. J Acquir Immune Defic Syndr (2010) 0.90
Biochemical and immunological characterization of MP65, a major mannoprotein antigen of the opportunistic human pathogen Candida albicans. Infect Immun (2000) 0.89
HIV protease inhibitors block oral epithelial cell DNA synthesis. Arch Oral Biol (2009) 0.85
Tetracycline-inducible expression of individual secreted aspartic proteases in Candida albicans allows isoenzyme-specific inhibitor screening. Antimicrob Agents Chemother (2007) 0.84
Proteomic signatures of human oral epithelial cells in HIV-infected subjects. PLoS One (2011) 0.84
Associations among the use of highly active antiretroviral therapy, oral candidiasis, oral Candida species and salivary immunoglobulin A in HIV-infected children. Oral Surg Oral Med Oral Pathol Oral Radiol Endod (2009) 0.80
Oral lesions among HIV-infected children on antiretroviral treatment in West Africa. Trop Med Int Health (2014) 0.80
Candidiasis (oropharyngeal). BMJ Clin Evid (2009) 0.80
The significance of oral health in HIV disease. Sex Transm Infect (2000) 0.78
Positive and negative aspects of the human immunodeficiency virus protease: development of inhibitors versus its role in AIDS pathogenesis. Microbiol Mol Biol Rev (2000) 0.78
Oral innate immunity in HIV infection in HAART era. J Oral Pathol Med (2015) 0.77
HIV aspartyl protease inhibitors as promising compounds against Candida albicans André Luis Souza dos Santos. World J Biol Chem (2010) 0.77
Oral thrush and HIV protease inhibitors. J Acquir Immune Defic Syndr (1999) 0.75
Candidiasis (oropharyngeal). BMJ Clin Evid (2013) 0.75
Candidiasis (oropharyngeal). BMJ Clin Evid (2012) 0.75
Infection with chikungunya virus in Italy: an outbreak in a temperate region. Lancet (2007) 10.81
Killer system: a simple method for differentiating Candida albicans strains. J Clin Microbiol (1983) 8.05
Methicillin-resistant Staphylococcus aureus (MRSA): burden of disease and control challenges in Europe. Euro Surveill (2010) 3.15
Lysis of growing yeast-form cells of Candida albicans by echinocandin: a cytological study. Sabouraudia (1981) 2.32
The pH of the host niche controls gene expression in and virulence of Candida albicans. Infect Immun (1998) 2.24
Chikungunya in north-eastern Italy: a summing up of the outbreak. Euro Surveill (2007) 2.07
Vaccine- and antigen-dependent type 1 and type 2 cytokine induction after primary vaccination of infants with whole-cell or acellular pertussis vaccines. Infect Immun (1997) 2.03
Yeast-mycelial conversion induced by N-acetyl-D-glucosamine in Candida albicans. Nature (1974) 2.03
Cell wall of Candida albicans: its functions and its impact on the host. Curr Top Med Mycol (1989) 2.00
Laboratory tools and strategies for methicillin-resistant Staphylococcus aureus screening, surveillance and typing: state of the art and unmet needs. Clin Microbiol Infect (2009) 1.95
Evidence for a correlation between proteinase secretion and vulvovaginal candidosis. J Infect Dis (1987) 1.89
Evidence for macrophage-mediated protection against lethal Candida albicans infection. Infect Immun (1986) 1.86
DNA fingerprinting and electrophoretic karyotype of environmental and clinical isolates of Candida parapsilosis. J Clin Microbiol (1991) 1.84
An outbreak of chikungunya fever in the province of Ravenna, Italy. Euro Surveill (2007) 1.81
Evidence for a role for secreted aspartate proteinase of Candida albicans in vulvovaginal candidiasis. J Infect Dis (1990) 1.80
Therapy of mucosal candidiasis by expression of an anti-idiotype in human commensal bacteria. Nat Biotechnol (2000) 1.79
Systematic literature analysis and review of targeted preventive measures to limit healthcare-associated infections by meticillin-resistant Staphylococcus aureus. Euro Surveill (2014) 1.79
Therapeutic potential of antiidiotypic single chain antibodies with yeast killer toxin activity. Nat Biotechnol (1997) 1.75
In vitro and in vivo anticandidal activity of human immunodeficiency virus protease inhibitors. J Infect Dis (1999) 1.72
The secreted aspartate proteinase of Candida albicans: physiology of secretion and virulence of a proteinase-deficient mutant. J Gen Microbiol (1990) 1.69
A mannoprotein constituent of Candida albicans that elicits different levels of delayed-type hypersensitivity, cytokine production, and anticandidal protection in mice. Infect Immun (1994) 1.68
Protective role of antimannan and anti-aspartyl proteinase antibodies in an experimental model of Candida albicans vaginitis in rats. Infect Immun (1997) 1.68
Evidence that members of the secretory aspartyl proteinase gene family, in particular SAP2, are virulence factors for Candida vaginitis. J Infect Dis (1999) 1.58
Induction of germ tube formation by N-acetyl-D-glucosamine in Candida albicans: uptake of inducer and germinative response. J Bacteriol (1982) 1.56
Production and characterisation of a monoclonal antibody to a cell-surface, glucomannoprotein constituent of Candida albicans and other pathogenic Candida species. J Med Microbiol (1988) 1.54
Rats clearing a vaginal infection by Candida albicans acquire specific, antibody-mediated resistance to vaginal reinfection. Infect Immun (1995) 1.50
Highly active antiretroviral therapy decreases the incidence of visceral leishmaniasis in HIV-infected individuals. AIDS (2000) 1.49
In vitro production of tumor necrosis factor by murine splenic macrophages stimulated with mannoprotein constituents of Candida albicans cell wall. Cell Immunol (1991) 1.49
Rising incidence of Candida parapsilosis fungemia in patients with hematologic malignancies: clinical aspects, predisposing factors, and differential pathogenicity of the causative strains. Clin Infect Dis (1996) 1.48
Visulization of new ultrastructural components in the cell wall of Candida albicans with fixatives containing TAPO. J Cell Biol (1972) 1.46
Agglutination of blastospores of Candida albicans by concanavalin A and its relationship with the distribution of mannan polymers and the ultrastructure of the cell wall. J Gen Microbiol (1978) 1.44
Idiotypic intravaginal vaccination to protect against candidal vaginitis by secretory, yeast killer toxin-like anti-idiotypic antibodies. J Immunol (1994) 1.42
Lymphoproliferative and cytotoxic responses of human peripheral blood mononuclear cells to mannoprotein constituents of Candida albicans. J Gen Microbiol (1990) 1.40
Breakthrough candidemia during antifungal treatment with fluconazole in patients with hematologic malignancies. Blood (1996) 1.40
Expression of Candida albicans SAP1 and SAP2 in experimental vaginitis. Infect Immun (1995) 1.39
A mannoprotein constituent of Candida albicans cooperates with antigen in the induction of a specific primary antibody response in cultures of human lymphocytes. J Biol Regul Homeost Agents (1991) 1.39
Cell wall components of Candida albicans as immunomodulators: induction of natural killer and macrophage-mediated peritoneal cell cytotoxicity in mice by mannoprotein and glucan fractions. J Gen Microbiol (1988) 1.38
Cytokine gene expression in human peripheral blood mononuclear cells stimulated by mannoprotein constituents from Candida albicans. Infect Immun (1993) 1.38
Identification of a 65-kDa mannoprotein as a main target of human cell-mediated immune response to Candida albicans. J Infect Dis (1993) 1.36
Blastoschizomyces capitatus: an emerging cause of invasive fungal disease in leukemia patients. Rev Infect Dis (1990) 1.34
Glycopeptide resistance among coagulase-negative staphylococci that cause bacteremia: epidemiological and clinical findings from a case-control study. Clin Infect Dis (2001) 1.34
Biotype diversity of Candida parapsilosis and its relationship to the clinical source and experimental pathogenicity. J Infect Dis (1995) 1.32
Bacterial pneumonia in HIV-infected patients: analysis of risk factors and prognostic indicators. J Acquir Immune Defic Syndr Hum Retrovirol (1998) 1.32
Avirulence of Candida albicans CaHK1 mutants in a murine model of hematogenously disseminated candidiasis. Infect Immun (1999) 1.30
Studies on the epidemiology of Aspergillus fumigatus infections in a university hospital. Eur J Epidemiol (1989) 1.29
Elevated aspartic proteinase secretion and experimental pathogenicity of Candida albicans isolates from oral cavities of subjects infected with human immunodeficiency virus. Infect Immun (1996) 1.29
Ultrastructural changes in the wall during germ-tube formation from blastospores of Candida albicans. J Gen Microbiol (1973) 1.29
Inducibility of germ-tube formation in Candida albicans at different phases of yeast growth. J Gen Microbiol (1979) 1.28
Reevaluation of the yeast killer phenomenon. J Clin Microbiol (1986) 1.28
Cell-mediated immune responses in four-year-old children after primary immunization with acellular pertussis vaccines. Infect Immun (1999) 1.25
Identification of a glucan-associated enolase as a main cell wall protein of Candida albicans and an indirect target of lipopeptide antimycotics. J Infect Dis (1996) 1.25
Ultrastructural changes in the cell wall of Candida albicans following cessation of growth and their possible relationship to the development of polyene resistance. J Gen Microbiol (1979) 1.24
Isolation, acid proteinase secretion, and experimental pathogenicity of Candida parapsilosis from outpatients with vaginitis. J Clin Microbiol (1989) 1.23
Differential chemokine response of human monocytes to yeast and hyphal forms of Candida albicans and its relation to the beta-1,6 glucan of the fungal cell wall. J Leukoc Biol (2000) 1.23
Filamentous growth and elevated vaginopathic potential of a nongerminative variant of Candida albicans expressing low virulence in systemic infection. Infect Immun (1993) 1.23
Use of killer toxins for computer-aided differentiation of Candida albicans strains. Mycopathologia (1985) 1.22
Protective immunity induced by low-virulence Candida albicans: cytokine production in the development of the anti-infectious state. Cell Immunol (1989) 1.21
Proliferation of human peripheral blood mononuclear cells induced by Candida albicans and its cell wall fractions. J Med Microbiol (1986) 1.20
Local anticandidal immune responses in a rat model of vaginal infection by and protection against Candida albicans. Infect Immun (2000) 1.20
A comparison of experimental pathogenicity of Candida species in cyclophosphamide-immunodepressed mice. Sabouraudia (1984) 1.19
Retrospective study of candidemia in patients with hematological malignancies. Clinical features, risk factors and outcome of 76 episodes. Eur J Haematol (1999) 1.19
Immunomodulation by a low-virulence, agerminative variant of Candida albicans. Further evidence for macrophage activation as one of the effector mechanisms of nonspecific anti-infectious protection. J Med Vet Mycol (1988) 1.18
CD4+ T-helper-cell responses in mice with low-level Candida albicans infection. Infect Immun (1996) 1.18
Serological analysis of dermatophyte isolates with monoclonal antibodies produced against Microsporum canis. J Clin Microbiol (1985) 1.17
CD8+ T lymphocytes provide helper activity for IgE synthesis in human immunodeficiency virus-infected patients with hyper-IgE. J Exp Med (1995) 1.16
Modulation of cell surface-associated mannoprotein antigen expression in experimental candidal vaginitis. Infect Immun (1994) 1.16
Strain differentiation of pathogenic yeasts by the killer system. Mycopathologia (1984) 1.16
Risk factors and mortality of healthcare-associated and community-acquired Staphylococcus aureus bacteraemia. Clin Microbiol Infect (2011) 1.15
Identification of a mannoprotein fraction from Candida albicans that enhances human polymorphonuclear leukocyte (PMNL) functions and stimulates lactoferrin in PMNL inhibition of candidal growth. J Infect Dis (1992) 1.13
Purification and biochemical characterization of a 65-kilodalton mannoprotein (MP65), a main target of anti-Candida cell-mediated immune responses in humans. Infect Immun (1996) 1.13
Differences in the antigenic expression of immunomodulatory mannoprotein constituents on yeast and mycelial forms of Candida albicans. J Gen Microbiol (1990) 1.13
Proliferative and cytotoxic responses to mannoproteins of Candida albicans by peripheral blood lymphocytes of HIV-infected subjects. Clin Exp Immunol (1991) 1.10
Biotyping and virulence properties of skin isolates of Candida parapsilosis. J Clin Microbiol (1999) 1.10
In-vitro killing of Candida species by murine immunoeffectors and its relationship to the experimental pathogenicity. Sabouraudia (1985) 1.09
Influx of multidrug-resistant, gram-negative bacteria in the hospital setting and the role of elderly patients with bacterial bloodstream infection. Infect Control Hosp Epidemiol (2009) 1.08
Human natural yeast killer toxin-like candidacidal antibodies. J Immunol (1996) 1.07
Antibodies, killer toxins and antifungal immunoprotection: a lesson from nature? Immunol Today (1997) 1.07
Nosocomial bloodstream infections in HIV-infected patients: attributable mortality and extension of hospital stay. J Acquir Immune Defic Syndr Hum Retrovirol (1998) 1.06
Vaginopathic and proteolytic Candida species in outpatients attending a gynaecology clinic. J Clin Pathol (1991) 1.06
Pneumothorax in HIV-infected patients: role of Pneumocystis carinii pneumonia and pulmonary tuberculosis. Eur Respir J (1997) 1.05
Biochemical and antigenic characterization of mannoprotein constituents released from yeast and mycelial forms of Candida albicans. J Med Vet Mycol (1991) 1.05
Nosocomial outbreak of systemic candidosis associated with parenteral nutrition. Infect Control Hosp Epidemiol (1990) 1.05
Differential cell surface expression of mannoprotein epitopes in yeast and mycelial forms of Candida albicans. Eur J Cell Biol (1993) 1.05